Status:

RECRUITING

Peroneal Electrical Nerve Stimulation in Pregnancy for Restless Legs Syndrome

Lead Sponsor:

Rhode Island Hospital

Collaborating Sponsors:

American College of Chest Physicians

Conditions:

Restless Leg Disorder

Restless Leg Syndrome (RLS)

Eligibility:

FEMALE

18+ years

Phase:

NA

Brief Summary

The goal of this study is to evaluate whether peroneal electrical nerve stimulation (PNS) using the TOMAC™ device is a feasible, acceptable, and safe non-pharmacologic intervention for managing Restle...

Detailed Description

This is a prospective, open-label, single-arm pilot study designed to assess the feasibility, acceptability, and preliminary safety of TOMAC™ peroneal electrical nerve stimulation (PNS) for the treatm...

Eligibility Criteria

Inclusion

  • Age ≥18 years
  • Pregnant individuals between 21 and 26 weeks' gestation at enrollment
  • Singleton pregnancy without known fetal anomalies
  • Confirmed clinical diagnosis of Restless Legs Syndrome (RLS) according to International Restless Legs Syndrome Study Group (IRLSSG) criteria, confirmed by a sleep medicine specialist to exclude RLS mimics
  • Able and willing to provide informed consent
  • Able and willing to comply with study procedures, including device usage, questionnaires, adherence diaries, and follow-up assessments up to 3 months postpartum

Exclusion

  • Pregnancy-related:
  • History of preterm labor
  • Known fetal anomalies identified prior to enrollment
  • Neurological and neuromuscular disorders:
  • Pre-existing neuromuscular disorders affecting balance or gait
  • Severe peripheral neuropathy involving the lower legs
  • Epilepsy or history of seizures
  • Cardiovascular and circulatory conditions:
  • History of deep vein thrombosis (DVT)
  • Circulatory conditions contraindicating peroneal nerve stimulation (PNS) device use
  • Dermatological conditions:
  • Skin conditions at device application sites
  • Known allergy to device materials
  • Other sleep disorders:
  • • Inadequately treated severe primary sleep disorders other than RLS (e.g., untreated severe sleep apnea, severe insomnia unrelated to RLS)
  • Device and treatment experience exclusions (based on RESTFUL trial criteria):
  • Prior use of the study device or any neurostimulation device for RLS treatment
  • Presence of active medical implants (e.g., pacemakers, spinal cord stimulators)
  • Other medical conditions:
  • Participants undergoing dialysis treatment
  • Severe psychiatric conditions (e.g., bipolar disorder, psychosis, severe anxiety or depression) that may interfere with adherence or accurate symptom reporting
  • Any condition deemed by investigators to pose safety risks or impede participation
  • Other exclusions:
  • Unable or unwilling to operate the device safely and independently
  • Unable to participate reliably in follow-up assessments or complete self-reported diaries

Key Trial Info

Start Date :

October 15 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 31 2026

Estimated Enrollment :

15 Patients enrolled

Trial Details

Trial ID

NCT07144631

Start Date

October 15 2025

End Date

October 31 2026

Last Update

November 12 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Rhode Island Hospital

Providence, Rhode Island, United States, 02903

2

Rhode Island Hospital

Providence, Rhode Island, United States, 02903